Clinical Evidence

Delve into clinical research studies and more

Clinical research lies at the heart of who we are. Vantive uses scientific evidence systematically, and transparently, to inform the development of new state-of-the-art solutions for patients around the world. Here you can find various studies, white papers and articles concerning important topics across the wide range of therapy areas served by Vantive.

HDx therapy enabled by the Theranova Dialyzer
Disruptive technologies for hemodialysis: medium and high cutoff membranes. Is the future now?
Visit resource site
HDx therapy enabled by the Theranova Dialyzer
Distribution of peripheral blood t cell subtypes in hemodialysis patients treated with medium cut-off membranes and high-flux membranes
Visit resource site
HDx therapy enabled by the Theranova Dialyzer
Effect of a medium cut-off dialyzer on protein-bound uremic toxins and mineral metabolism markers in patients on hemodialysis.
Visit resource site
HDx therapy enabled by the Theranova Dialyzer
Effect of expanded hemodialysis on body composition and nutritional status
Visit resource site
HDx therapy enabled by the Theranova Dialyzer
Effect of Expanded Hemodialysis with Theranova® in Patients with COVID-19
Visit resource site
HDx therapy enabled by the Theranova Dialyzer
Effect of hemodialysis with medium cut-off versus high-flux membranes on endothelial function of chronic kidney disease patients
Visit resource site
HDx therapy enabled by the Theranova Dialyzer
Effect of medium cut-off and high-flux hemodialysis membranes on blood pressure assessed by ambulatory blood pressure monitoring.
Visit resource site
HDx therapy enabled by the Theranova Dialyzer
Effectiveness of medium cut-off vs high flux dialyzers: a propensity score matching cohort study
Visit resource site
HDx therapy enabled by the Theranova Dialyzer
Effects of a medium cut-off (Theranova®) dialyser on haemodialysis patients: a prospective, cross-over study
Visit resource site
HDx therapy enabled by the Theranova Dialyzer
Effects of Different Dialysis Strategies on Inflammatory Cytokine Profile in Maintenance Hemodialysis Patients with COVID-19: A Randomized Trial.
Visit resource site
HDx therapy enabled by the Theranova Dialyzer
Effects of different dialysis techniques on inflammation in maintenance hemodialysis patients with covid-19: a randomized study
Visit resource site
HDx therapy enabled by the Theranova Dialyzer
Effects of Expanded Hemodialysis Therapy on Clinical Outcomes
Visit resource site

Important Safety Information

INTENDED USE

The Theranova Dialyzer is indicated for patients with chronic kidney failure who are prescribed intermittent hemodialysis. It provides an expanded solute removal profile with increased removal of various middle molecules (up to 45 kDa) that may play a pathologic role in the uremic clinical syndrome. The Theranova Dialyzer is not intended for hemofiltration or hemodiafiltration therapy. The total extracorporeal blood volume for the Theranova Dialyzer and the set should represent less than 10% of the patient's blood volume.

For single use only.

 

Rx Only. For safe and proper use of the products mentioned herein, please refer to the appropriate Operator’s Manual or Instructions for Use.

 

Vantive, HDx and Theranova are trademarks of Vantive Health LLC or its affiliates.